$38.48
2.09% yesterday
Nasdaq, Aug 25, 10:00 pm CET
ISIN
US1421521071
Symbol
CAI

Caris Life Sciences Stock price

$39.30
+9.01 29.75% 1M
+18.30 87.14% 6M
+18.30 87.14% YTD
+18.30 87.14% 1Y
+18.30 87.14% 3Y
+18.30 87.14% 5Y
+18.30 87.14% 10Y
+18.30 87.14% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+1.18 3.10%
ISIN
US1421521071
Symbol
CAI

Key metrics

Basic
Market capitalization
$11.1b
Enterprise Value
$11.4b
Net debt
$343.3m
Cash
$33.4m
Shares outstanding
-
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | 16.8
EV/Sales
- | 17.3
EV/FCF
-
P/B
negative
Financial Health
Equity Ratio
-80.6%
Return on Equity
136.5%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
- | $658.4m
EBITDA
- | $-66.0m
EBIT
- | $-111.2m
Net Income
- | -
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | 59.7%
EBITDA
- | 74.3%
EBIT
- | 56.8%
Net Income
- | -
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
- | -10.0%
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
-
Short interest
-
Employees
-
Rev per Employee
-
Show more

Is Caris Life Sciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Caris Life Sciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Caris Life Sciences forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Caris Life Sciences forecast:

Buy
90%
Hold
10%

Financial data from Caris Life Sciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter Annually
Mar '25
+/-
%
121 121
50% 50%
100%
- Direct Costs 64 64
17% 17%
53%
57 57
119% 119%
47%
- Selling and Administrative Expenses 92 92
10% 10%
76%
- Research and Development Expense 23 23
33% 33%
19%
-51 -51
32% 32%
-42%
- Depreciation and Amortization 7.05 7.05
60% 60%
6%
EBIT (Operating Income) EBIT -58 -58
37% 37%
-48%
Net Profit -127 -127
5% 5%
-105%

In millions USD.

Don't miss a Thing! We will send you all news about Caris Life Sciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Caris Life Sciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Irving, Texas. The company went IPO on 2025-06-18. Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The firm develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.

Head office United States
Website www.carislifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today